cinv

Azasetron hydrochloride (Y-25130 HCl) 是一种苯甲酰胺的衍生物，是有效的、选择性的5-HT3受体拮抗剂，可用于化疗引起的恶心呕吐研究。

Tunicamycin VIII 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T124297，CAS号为 73942-07-1。

Tunicamycin VII 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T124449，CAS号为 66081-36-5。

5-HT2A 5-HT2C inverse agonist 1 是一款具有抗精神病疗效的双重5-HT2A和5-HT2C反激动剂。该化合物在 MK-801 诱导的小鼠模型中表现出显著疗效，并且具有抑制hERG的功能，有助于降低心血管风险。5-HT2A 5-HT2C inverse agonist 1 展示了其在精神病研究中的应用潜力。

Bekanamycin sulfate is an agent of bioactive chemicals.

Albacarcin V is a biochemical.

Corynecin V is a chloramphenicol-like bacterial metabolite originally isolated from Corynebacterium.

Tunicamycin 15:1 is a mixture of tunicamycin structural isomers that contains a 15-carbon N-acyl chain with variable branching patterns.References Tunicamycin 15:1 is a mixture of tunicamycin structural isomers that contains a 15-carbon N-acyl chain with variable branching patterns. References

Actinomycin X2 (Actinomycin V) is a compound synthesized by various species of Streptomyces. It displays potent inhibition against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.25 μg mL. Actinomycin X2 possesses potential applications in the treatment of both cancer and bacterial infections.

Cucurbitacin V 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN5990，CAS号为 152340-37-9。

16-Desoxycucurbitacin V 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN5993，CAS号为 2081098-85-1。

Gilvocarcin V, a metabolite from Actinomycete DO-38, exhibits potent antibacterial, antifungal, and antiviral activity.

(R,R)-Palonosetron Hydrochloride is the active enantiomer of Palonosetron

Casopitant (GW679769) 是一种口服有效的神经激肽-1 (NK1) 受体拮抗剂，用于研究化疗引起的恶心和呕吐 (CINV) 以及术后恶心和呕吐 (PONV)。

Palonosetron, a 5-HT3 antagonist with Ki of 0.17 nM, is used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).

Rolapitant (SCH619734) 是一种高效选择性具有口服活性的神经激肽 1 受体抑制剂，Ki 值为0.66 nM。

Rolapitant, also known as SCH-619734, is an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy.